Ann Marie Navar explains how enlicitide’s sustained LDL-C lowering, favorable tolerability, and structured dosing may improve adherence and expand oral add-on options for patients not at goal on statins.

Pharmacists are critical in supporting GLP-1 therapy success through proactive expectation-setting.

NCCN updates can guide pharmacists to tailor chemotherapy for HR+/HER2- breast cancer using MammaPrint and FLEX survival data.

The VESALIUS-CV trial demonstrates that adding evolocumab to maximally tolerated statin therapy significantly reduces major cardiovascular events in both high-risk primary and secondary prevention patients.

Ongoing variation in vaccine schedule implementation requires pharmacists and clinicians to collaborate closely, reinforce evidence-based care, and monitor vulnerable populations for gaps in immunization coverage.

Pharmacists play a vital role in countering GLP-1 misinformation.

Changes to the federal childhood vaccine schedule have created confusion and variation in practice, placing added responsibility on clinicians and pharmacists to educate patients and ensure evidence-based care.

Pharmacists enhance multiple sclerosis care through collaborative practice agreements, improving patient outcomes and bridging gaps in treatment and education.

Experts discuss how atebimetinib and adjusted chemotherapy schedules enhance tolerability and treatment duration for pancreatic cancer patients.